CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
May 17th 2024
Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy.
Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd
October 1st 2023Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.
FDA Approval of Elrexfio Represents ‘a Very Hopeful Time’ for Heavily Pretreated Multiple Myeloma
August 28th 2023Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.
FDA Approves Elrexfio for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
August 14th 2023The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.